Porphyria Cutanea Tarda in a Patient with End-Stage Renal Disease: A Case of Successful Treatment with Deferoxamine and Ferric Carboxymaltose
Porphyria cutanea tarda (PCT) is a rare disease, with a strong association with hepatitis C virus. PCT is particularly problematic in end-stage renal disease patients as they have no renal excretion of porphyrins and these are poorly dialyzed. Also, conventional treatment of PCT is compromised in th...
Saved in:
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2017-01-01
|
| Series: | Case Reports in Nephrology |
| Online Access: | http://dx.doi.org/10.1155/2017/4591871 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832558709604089856 |
|---|---|
| author | Natacha Rodrigues Fernando Caeiro Alice Santana Teresa Mendes Leonor Lopes |
| author_facet | Natacha Rodrigues Fernando Caeiro Alice Santana Teresa Mendes Leonor Lopes |
| author_sort | Natacha Rodrigues |
| collection | DOAJ |
| description | Porphyria cutanea tarda (PCT) is a rare disease, with a strong association with hepatitis C virus. PCT is particularly problematic in end-stage renal disease patients as they have no renal excretion of porphyrins and these are poorly dialyzed. Also, conventional treatment of PCT is compromised in these patients as hydroxychloroquine is contraindicated, phlebotomies with the stipulated frequency are poorly tolerated in already anaemia-prone patients, and iron-chelating agents are less efficient in removing iron and contribute to worsening anaemia. The authors report a patient on haemodialysis, with hepatitis C infection, that is diagnosed with PCT. Despite the good clinical results with deferoxamine, she became dependent on blood transfusions because of her ferropenic state. Every time oxide iron was started, the patient developed clinical features of the disease, resolving after the suspension of the drug. A decision was made to start the patient on ferric carboxymaltose, which was well tolerated without disease symptoms and need of further blood transfusions. This case suggests that deferoxamine is efficient in treatment of porphyria cutanea tarda. Also, ferric carboxymaltose may be a valuable option for refractory anaemia in patients with this disease and end-stage renal disease, as it seems to provide iron without clinical relapse of the disease. |
| format | Article |
| id | doaj-art-2a03c46b8bd444e38b735b3569a7340a |
| institution | Kabale University |
| issn | 2090-6641 2090-665X |
| language | English |
| publishDate | 2017-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | Case Reports in Nephrology |
| spelling | doaj-art-2a03c46b8bd444e38b735b3569a7340a2025-02-03T01:31:47ZengWileyCase Reports in Nephrology2090-66412090-665X2017-01-01201710.1155/2017/45918714591871Porphyria Cutanea Tarda in a Patient with End-Stage Renal Disease: A Case of Successful Treatment with Deferoxamine and Ferric CarboxymaltoseNatacha Rodrigues0Fernando Caeiro1Alice Santana2Teresa Mendes3Leonor Lopes4Hemodialysis Unit Diaverum Cruz Vermelha Portuguesa, Lisbon, PortugalHemodialysis Unit Diaverum Cruz Vermelha Portuguesa, Lisbon, PortugalHemodialysis Unit Diaverum Cruz Vermelha Portuguesa, Lisbon, PortugalHemodialysis Unit Diaverum Cruz Vermelha Portuguesa, Lisbon, PortugalDepartment of Dermatology, Centro Hospitalar Lisboa Norte, Lisbon, PortugalPorphyria cutanea tarda (PCT) is a rare disease, with a strong association with hepatitis C virus. PCT is particularly problematic in end-stage renal disease patients as they have no renal excretion of porphyrins and these are poorly dialyzed. Also, conventional treatment of PCT is compromised in these patients as hydroxychloroquine is contraindicated, phlebotomies with the stipulated frequency are poorly tolerated in already anaemia-prone patients, and iron-chelating agents are less efficient in removing iron and contribute to worsening anaemia. The authors report a patient on haemodialysis, with hepatitis C infection, that is diagnosed with PCT. Despite the good clinical results with deferoxamine, she became dependent on blood transfusions because of her ferropenic state. Every time oxide iron was started, the patient developed clinical features of the disease, resolving after the suspension of the drug. A decision was made to start the patient on ferric carboxymaltose, which was well tolerated without disease symptoms and need of further blood transfusions. This case suggests that deferoxamine is efficient in treatment of porphyria cutanea tarda. Also, ferric carboxymaltose may be a valuable option for refractory anaemia in patients with this disease and end-stage renal disease, as it seems to provide iron without clinical relapse of the disease.http://dx.doi.org/10.1155/2017/4591871 |
| spellingShingle | Natacha Rodrigues Fernando Caeiro Alice Santana Teresa Mendes Leonor Lopes Porphyria Cutanea Tarda in a Patient with End-Stage Renal Disease: A Case of Successful Treatment with Deferoxamine and Ferric Carboxymaltose Case Reports in Nephrology |
| title | Porphyria Cutanea Tarda in a Patient with End-Stage Renal Disease: A Case of Successful Treatment with Deferoxamine and Ferric Carboxymaltose |
| title_full | Porphyria Cutanea Tarda in a Patient with End-Stage Renal Disease: A Case of Successful Treatment with Deferoxamine and Ferric Carboxymaltose |
| title_fullStr | Porphyria Cutanea Tarda in a Patient with End-Stage Renal Disease: A Case of Successful Treatment with Deferoxamine and Ferric Carboxymaltose |
| title_full_unstemmed | Porphyria Cutanea Tarda in a Patient with End-Stage Renal Disease: A Case of Successful Treatment with Deferoxamine and Ferric Carboxymaltose |
| title_short | Porphyria Cutanea Tarda in a Patient with End-Stage Renal Disease: A Case of Successful Treatment with Deferoxamine and Ferric Carboxymaltose |
| title_sort | porphyria cutanea tarda in a patient with end stage renal disease a case of successful treatment with deferoxamine and ferric carboxymaltose |
| url | http://dx.doi.org/10.1155/2017/4591871 |
| work_keys_str_mv | AT natacharodrigues porphyriacutaneatardainapatientwithendstagerenaldiseaseacaseofsuccessfultreatmentwithdeferoxamineandferriccarboxymaltose AT fernandocaeiro porphyriacutaneatardainapatientwithendstagerenaldiseaseacaseofsuccessfultreatmentwithdeferoxamineandferriccarboxymaltose AT alicesantana porphyriacutaneatardainapatientwithendstagerenaldiseaseacaseofsuccessfultreatmentwithdeferoxamineandferriccarboxymaltose AT teresamendes porphyriacutaneatardainapatientwithendstagerenaldiseaseacaseofsuccessfultreatmentwithdeferoxamineandferriccarboxymaltose AT leonorlopes porphyriacutaneatardainapatientwithendstagerenaldiseaseacaseofsuccessfultreatmentwithdeferoxamineandferriccarboxymaltose |